丁螺环酮增效治疗慢性精神分裂症阴性症状的随机双盲对照研究

A comparative study of buspirone in the treatment of negative symptoms of chronic schizophrenia

目的观察丁螺环酮增效治疗慢性精神分裂症阴性症状的临床疗效和安全性评估.方法将60例以阴性症状为主的慢性精神分裂症住院患者按随机数字表法分为2组,在原抗精神病药物基础上,分别联用丁螺环酮或安慰剂,疗程共12周.于治疗前和治疗后第4、8、12周末采用阳性和阴性症状量表(PANSS)及阴性症状量表(SANS)评估疗效,采用住院精神病人社会功能评定量表(SSPI)评估患者社会功能,症状量表(TESS)评估治疗过程的安全性.结果研究组PANSS阴性因子总分、SANS总分及SSPI总分在第12周末均显著低于对照组,差异有统计学意义(P<0.01);2组间不良反应发生率差异无统计学意义(P>0.05).结论联用丁螺环酮对改善慢性精神分裂症阴性症状有增效作用,促进社会功能的恢复,且安全性好.

Objective To investigate the effect and safety of buspirone in improving negative symptoms of chronic schizophrenia.Methods In this study,60 patients with chronic schizophrenia received in random order antipsychotic drug with buspirone or placebo for 12 weeks.The efficacy was assessed by the positive and negative symptoms scale(PANSS)and the scale for the assessment of negative symptoms scale(SANS)at baseline,and 4 weeks,8 weeks and 12 weeks after baseline.The social function was assessed by social function assessment scale for inpatients with psychosis(SSPI),and the safety was assessed by the symptom scale(TESS).Results There was a significant reduction in total scores of PANSS in the negative subscale.The scores of negative subscale,total scores of SANS and total scores of SSPI at 12 week.The difference was significant(P<0.01).The difference between the buspirone and the placebo in the frequency of adverse effects was not significant(P>0.05).Conclusion The results suggest that co-treatment with buspirone may improve the negative symptoms of schizophrenia,promote social function recovery,and have good safety.